A study in July 2024 by researchers at Mass Eye and Ear in Boston found that people taking semaglutide for type 2 diabetes or weight loss had a higher risk of developing nonarteritic anterior ischemic optic neuropathy, an eye condition that can cause blindness, than people taking medications other than GLP-1 drugs for diabetes or obesity
Pharmacokinetic interactions involve changes in drug absorption, distribution, metabolism, or elimination
Take Ashley Dunham, for instance - she lost 70 pounds in just 5.5 months and saw her menstrual cycles return to normal
FDA-approved medication pathways require evaluation by licensed medical professionals
(tipranks.com) Outlook for formulation scientists and excipient developers For formulation experts, this development highlights several key trends shaping the future of oral biologics The shift from single enhancer systems to multifunctional excipient platforms The increasing importance of dosage form engineering alongside excipient selection The need to tailor delivery systems to the specific properties of each peptide The growing role of pharmacokinetic optimization in early formulation screening As the GLP 1 field evolves, excipient driven innovation will remain central to enabling oral delivery of increasingly complex peptide therapeutics
The above results demonstrate that TGF- induces ferroptosis accumulation, which Fer-1 effectively ameliorates in HK-2 cells